167 related articles for article (PubMed ID: 27767359)
1. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease.
Keino H; Watanabe T; Nakayama M; Komagata Y; Fukuoka K; Okada AA
Br J Ophthalmol; 2021 Nov; 105(11):1525-1533. PubMed ID: 32972915
[TBL] [Abstract][Full Text] [Related]
3. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
4. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
Okada AA; Goto H; Ohno S; Mochizuki M;
Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
Yalçindag N; Köse HC
Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
[No Abstract] [Full Text] [Related]
9. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of disrupted photoreceptor layer in uveitis associated with Behçet's disease by infliximab treatment.
Takeuchi M; Harimoto K; Taguchi M; Sakurai Y
BMC Ophthalmol; 2015 Dec; 15():177. PubMed ID: 26653575
[TBL] [Abstract][Full Text] [Related]
13. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
Köse HC; Yalçındağ N
Ocul Immunol Inflamm; 2022 Jan; 30(1):203-207. PubMed ID: 32779960
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of infliximab in patients with Behçet syndrome and severe uveoretinitis. Report of five cases].
Merino G; Varas G; Díaz G; Gutiérrez M; Massardo L; Pacheco D; Villarroel F; Cuchacovich M
Rev Med Chil; 2006 Jul; 134(7):875-82. PubMed ID: 17130971
[TBL] [Abstract][Full Text] [Related]
15. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
[TBL] [Abstract][Full Text] [Related]
16. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
[TBL] [Abstract][Full Text] [Related]
17. Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.
Kuroyanagi K; Sakai T; Kohno H; Okano K; Akiyama G; Aoyagi R; Inaba M; Tsuneoka H
Jpn J Ophthalmol; 2015 Nov; 59(6):401-8. PubMed ID: 26318435
[TBL] [Abstract][Full Text] [Related]
18. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
[TBL] [Abstract][Full Text] [Related]
20. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
Martín-Varillas JL; Atienza-Mateo B; Calvo-Rio V; Beltrán E; Sánchez-Bursón J; Adán A; Hernández-Garfella M; Valls-Pascual E; Sellas-Fernández A; Ortego N; Maíz O; Torre I; Fernández-Espartero C; Jovani V; Peiteado D; Valle DD; Aurrecoechea E; Caracuel MA; García-González AJ; Álvarez ER; Vegas-Revenga N; Demetrio-Pablo R; Castañeda S; González-Gay MA; Hernández JL; Blanco R;
J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
